Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C, Lok A, Tessoulin B, Gastinne T, Mahé B, Dubruille V, Blin N, Touzeau C, Moreau A, Bossard C, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Chevallier P, Moreau P, Leux C, Le Gouill S.
Sortais C, et al. Among authors: moreau p, moreau a.
Ann Hematol. 2020 Jul;99(7):1595-1604. doi: 10.1007/s00277-020-04025-2. Epub 2020 May 16.
Ann Hematol. 2020.
PMID: 32417940